“In a phase 2 study, men with metastatic castration-resistant prostate cancer whose tumors harbored certain DNA-repair defects were much more likely to respond to the oral PARP (poly [ADP-ribose] polymerase) inhibitor olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) than their peers whose tumor
“In a phase 2 study, men with metastatic castration-resistant prostate cancer whose tumors harbored certain DNA-repair defects were much more likely to respond to the oral PARP (poly [ADP-ribose] polymerase) inhibitor olaparib (Lynparza, AstraZeneca Pharmaceuticals LP) than their peers whose tumor
このブックマークにはスターがありません。
最初のスターをつけてみよう！
Coming: Prostate Cancer Treatment Guided by Biomarkers
1 人がブックマーク・1 件のコメント
＼ コメントが サクサク読める アプリです ／